AICAR (Acadesine)
A nucleotide analogue that directly activates AMPK - the master metabolic sensor - independently of AMP levels. Dubbed the 'exercise in a pill' in landmark Salk Institute research, AICAR increased running endurance by 44% in sedentary mice without any exercise training. Currently prohibited by WADA.
Reviewed & fact-checked by
Dr. Jane Smith, MD, PhDChief Medical Reviewer · Last updated: March 25, 2026
Medical Disclaimer: The information on this page is for educational and research purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
The Exercise Pill: What the Research Actually Shows
In 2008, researchers at the Salk Institute published landmark findings in Cell: AICAR alone (without any exercise training) increased running endurance in mice by 44%. Combined with GW501516 (a PPAR-delta agonist), the increase reached 77%. The study demonstrated that AMPK activation through AICAR could reprogram skeletal muscle metabolism to favour fat oxidation and endurance, mimicking the adaptive effects of aerobic exercise training.
This generated enormous interest but also significant caution -- the metabolic effects of AICAR are profound and not without risk.
Mechanism of Action
AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) is converted intracellularly to ZMP, a structural analogue of AMP. ZMP binds to the same regulatory site as AMP on AMPK, activating it directly:
- AMPK activation -- increases glucose uptake via GLUT4 translocation, enhances fatty acid oxidation, and suppresses hepatic glucose production
- Mitochondrial biogenesis -- via downstream PGC-1alpha activation, increases mitochondrial density in skeletal muscle
- Glycogen synthesis inhibition -- redirects glucose toward oxidation rather than storage
- Cardiac metabolism -- in ischaemic myocardium, AICAR has demonstrated protective effects by shifting energy metabolism
Important Safety Considerations
AICAR carries a higher risk profile than most compounds on this site. Key concerns:
Hypoglycaemia: AICAR significantly lowers blood glucose. This is particularly dangerous in individuals on diabetes medications. Blood glucose monitoring before and after administration is essential.
Haemolytic anaemia: Prolonged AICAR use can disrupt the adenosine metabolism pathway in red blood cells, causing haemolysis. Complete blood count monitoring is warranted with any extended protocol.
WADA prohibition: AICAR is on WADA's prohibited list in all sports, in and out of competition. Any athlete subject to anti-doping testing should not use this compound.
This compound is for research purposes only. Medical supervision is strongly recommended.
Stacking Interactions
How AICAR (Acadesine) interacts with other compounds
Advanced metabolic stack. AICAR is the more potent AMPK activator; MOTS-c adds mitochondrial biogenesis. Monitor glucose closely. Not recommended without medical oversight.
NMN raises NAD+ which AMPK pathways utilise for sirtuin activation. AICAR activates AMPK directly. Both improve mitochondrial function through related pathways.
Safety Profile — Tier C
Use caution — limited human data
Contraindications
- ●Cardiovascular disease - AICAR significantly alters cardiac metabolism
- ●Diabetes on insulin or sulphonylureas - profound glucose-lowering effect
- ●Competitive athletes - WADA-prohibited substance
- ●Pregnancy - insufficient data
Side Effects
- ●Significant hypoglycaemia risk - monitor blood glucose carefully
- ●Haemolytic anaemia with prolonged use (mechanism: adenosine pathway disruption)
- ●Injection site reactions
- ●Cardiac arrhythmia risk at high doses
- ●Headache and dizziness